Previous 10 | Next 10 |
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D...
Adverum Biotechnologies ( ADVM +16% ) is up on almost 20% higher volume in response to its announcement that the FDA has lifted the clinical hold on the second cohort in a Phase 1 study, OPTIC , evaluating lead gene therapy ADVM-022 (AAV.7m8-aflibercept) in patients with wet age-rel...
FDA Lifts Clinical Hold on Second Cohort to Allow Dose Escalation Robust Preliminary Anatomical Response from First Cohort Leads Adverum to Begin Dosing Second Cohort at Lower Dose MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM),...
Adverum Biotechnologies (NASDAQ: ADVM ): Q1 GAAP EPS of -$0.23 beats by $0.04 . More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
MENLO PARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2019 and provided a corp...
Independent Directors Rekha Hemrajani, James Scopa and Mark Lupher Added to the Board Patrick Machado Appointed as Board Chair; Paul Cleveland Retires from the Board MENLO PARK, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stag...
- Oral Presentation Today at 10:45 am ET at the ASGCT 22 nd Annual Meeting - - ADVM-022 Was Demonstrated to be Safe and Well Tolerated, Provided Long-term, Sustained Aflibercept Expression out to 30 Months Following a Single Intravitreal Injection - - Long-term Aflibercept Ex...
MENLO PARK, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, presented today for the first time preclinical data on sequentially dosing a contralateral ey...
Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...
MENLO PARK, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Thomas Leung as chief financial officer. Mr. Leung w...
News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
2024-04-27 03:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the us...
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark int...